UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in our charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure
The information included in Item 8.01 relating to the new meeting date for the 2023 Annual Meeting of Stockholders is incorporated herein by reference. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. By furnishing this information on this Current Report on Form 8-K, we make no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
Item 8.01 Other Events
On November 29, 2022, the Company’s Board of Directors approved the change of the meeting date for the 2023 Annual Meeting of Stockholders from January 16, 2023 to January 19, 2023. No change was made with respect to the record date. Accordingly, stockholders of record as of December 6, 2022, will continue to be entitled to notice of and to vote at the Annual Meeting in the manner described in the proxy statement. A proxy statement regarding the 2023 Annual Meeting of stockholders will be filed with the Securities and Exchange Commission and provided to the stockholders.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |
99.1 | Press Release dated December 1, 2022 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Allarity Therapeutics, Inc. | ||
By: | /s/ James G. Cullem | |
James G. Cullem | ||
Chief Executive Officer | ||
Dated: December 1, 2022 |
2
Exhibit 99.1
PRESS RELEASE
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting
and Sets New Record Date
Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the Company’s adjourned 2022 Annual Stockholders Meeting (“2022 ASM”) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (“2023 ASM”) will be held, as a virtual meeting, on January 19, 2023.
As previously announced, the Company’s 2022 ASM on November 4, 2022 was adjourned to December 2, 2022, without any business being conducted to allow additional time to achieve quorum and for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (“SEC”) on September 19, 2022.
The annual meeting was rescheduled to January 19, 2023 in light of the new proposals to be considered at the annual meeting. Stockholders of record as of December 6, 2022, will be entitled to notice of, and to vote at, the 2023 ASM. A proxy statement for the 2023 ASM, to be held on January 19, 2023, will be filed with the SEC and notice will be provided to the stockholders of record on or about December 9, 2022. The Company, however, reserves the right to change the record date prior to the 2023 ASM.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of four drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor being prepared for a Phase 1b combination study together with stenoparib; IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. for the treatment of second-line metastatic breast cancer and in Phase 2 development in Europe for the same indication; and 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS. LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP®, is being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Company’s website at www.Allarity.com
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP® score, the therapeutic response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP® is based on messenger RNA from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The DRP® platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.
Follow Allarity on Social Media
Facebook: https://www.facebook.com/AllarityTx/
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, all statements under the heading “Anticipated Milestones in 2022,” statements relating to the Company’s NDA submission for dovitinib and its PMA submission for the drug-specific DRP® companion diagnostic for dovitinib, any statements related to ongoing clinical trials for stenoparib for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K for the year ended December 31, 2021 filed today with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
Thomas Jensen
SVP of Investor Relations
investorrelations@allarity.com
Investor Relations:
Chuck Padala
LifeSci Advisors
+1 (646) 627-8390
chuck@lifesciadvisors.com
U.S. Media Contact:
Mike Beyer
Sam Brown, Inc.
+1 (312) 961-2502
mikebeyer@sambrown.com
EU Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Cover |
Nov. 29, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Nov. 29, 2022 |
Entity File Number | 001-41160 |
Entity Registrant Name | ALLARITY THERAPEUTICS, INC. |
Entity Central Index Key | 0001860657 |
Entity Tax Identification Number | 87-2147982 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 22 School Street |
Entity Address, Address Line Two | 2nd Floor |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02108 |
City Area Code | (401) |
Local Phone Number | 426-4664 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | ALLR |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
M-8?20$3;8T.P6BP^0"X99K>]9!:G
]@1RYR1P'E'!W;5]N%%M)-,A21I))\M]7LN-<
M?ECRT@ 6B5N>)!#I:ME_KPT'M*9W_&Z?7X&2C\,:*I?/S$BRR7]#5
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M4@K5- K>C^N&_A:Z49K1C1JU"# 25IMH16@\U A.\6Z1_KH, '968O<^98L0.[NU"JH0KEA,7&C"9I)G-^*T&D/MF%2
M@H>PM!(!,)4XH/8JM5A&]XHQD!?M[E![?.-?<*9+!<12)CDA$Y<(B<#""\NE
M6!W%L@LIBWPDWOF6R[-H@*4JC4JV[<,2?!%T@!55IB8]9H$#XDB>Q0E?$P),
M$+<3"L*&R&%\ 50B9+-B\7*)EE=,;G+F
M@![M4 _E\PE-S01ZE'W7%:5O]>K][@[P8'QZ",*&)=2B&6)_&4V8N+!?A.!5
M8RAH+^5SZCLM\ND@;^)?0%5F!,Q[V+)D)-HAD Y"A"N/B,$7113QUUJ45,
M^5D[&BLZP'88)_)0 H2#E'CQS\-ST RI7X*PQQMH5PT_J(2%/M4NJ3A2@8I[WL&6EQ:A6$7LA$$
ME9 5.PZ_!E-EJQ01.=TSH[Q=28N-3REK]FS&K0I;P,!I(!]4Q+$F)IRQSJ/M&%E[6C"2("T2\&
MY)V%',%O:G)(./F>BY%9:=RLPZP 0A5RP?NX#/J*4P9(S.X? ')Z2P_8Q.FN6RA
M-6HB"70R"CDN_4-/VLM8(-*>(NP,39G9OIA-'S^ 6V$(F\%;>,)@ X:$9R(@
MJ!5X1=P_Z[(4!G6^4?%+?GWTJ2N%";X%1*L6$G$H$L)FX)GD$>;JA-]DU4&U
MBKB\8"LKS3]A%7O1RB]7&?5F:55<=<+%?6(_ 7$_$9]^J9 C5KP$VP]O=D'A
MQ2[[TIZ#FLGX9/D)@^1<&&$%[-7P&,0(\G3ODS!>Z!]NI2C7^KUQQ^Y.%_)J
M=(JADSM"6G9?C0(G,WZFR$PG$"0= =8!^*$^-HFJ.4!\X4RY:E>